Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five brokerages that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $12.40.
INO has been the topic of several research analyst reports. HC Wainwright lowered their price objective on shares of Inovio Pharmaceuticals from $5.00 to $3.00 and set a "neutral" rating on the stock in a research report on Monday, January 13th. JMP Securities reissued a "market outperform" rating and set a $18.00 price target on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. Oppenheimer decreased their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an "outperform" rating for the company in a research report on Monday, November 18th. Finally, Royal Bank of Canada lowered their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research note on Friday, November 15th.
Read Our Latest Stock Report on Inovio Pharmaceuticals
Large investors have recently made changes to their positions in the company. Wolverine Asset Management LLC acquired a new stake in shares of Inovio Pharmaceuticals in the fourth quarter worth about $178,000. Dimensional Fund Advisors LP acquired a new stake in Inovio Pharmaceuticals in the 2nd quarter worth approximately $605,000. Wellington Management Group LLP bought a new stake in Inovio Pharmaceuticals during the third quarter worth approximately $379,000. State Street Corp grew its holdings in Inovio Pharmaceuticals by 11.7% during the third quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company's stock valued at $2,836,000 after purchasing an additional 51,414 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Inovio Pharmaceuticals by 6.7% in the third quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company's stock valued at $3,594,000 after purchasing an additional 38,833 shares during the period. Institutional investors own 26.79% of the company's stock.
Inovio Pharmaceuticals stock opened at $2.00 on Tuesday. Inovio Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $14.75. The firm's 50 day simple moving average is $2.42 and its 200-day simple moving average is $5.15.
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Inovio Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.
While Inovio Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.